<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631096</url>
  </required_header>
  <id_info>
    <org_study_id>ARB-001467-002</org_study_id>
    <nct_id>NCT02631096</nct_id>
  </id_info>
  <brief_title>Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</brief_title>
  <official_title>A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbutus Biopharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the
      safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of
      intravenous ARB-001467
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative
      subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be
      enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus
      (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with
      entecavir or tenofovir for at least 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single Blind (Subject) in cohort 1-3, Open label in Cohort 4</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment.</measure>
    <time_frame>28 days post last infusion</time_frame>
    <description>To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).</measure>
    <time_frame>Up to 36 Weeks</time_frame>
    <description>To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4).</measure>
    <time_frame>Up to 36 Weeks</time_frame>
    <description>To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (cohort 1-3) and Week 36 (Cohort 4).</measure>
    <time_frame>Up to 36 Weeks</time_frame>
    <description>To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf) partial, AUCs, T1/2, volume of distribution (VD) and clearance (CL) -baseline through Day 85 or Week 36.</measure>
    <time_frame>Up to 36 Weeks</time_frame>
    <description>To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate antiviral activity of ARB 001467 for up to 72 weeks after the first dose of study treatment.</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The proportion of subjects in each dose level cohort with ≥0.5 log10 HBsAg decrease from baseline at EOS, and for these subjects, the changes from baseline (expressed as percentage and log10 change) in the following virologic markers will be assessed throughout the study:
Quantitative HBV surface antigen (HBsAg)
Quantitative HBV surface antibody (HBsAb)
Quantitative HBV DNA and HBV-RNA (viral load)
For the HBeAg positive cohort only:
- Quantitative HBV e antigen (HBeAg)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>0.2 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARB-001467 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg/kg ARB-001467</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB-001467</intervention_name>
    <description>An IV infusion of ARB-001467</description>
    <arm_group_label>0.2 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>0.4 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>0.4 mg/kg ARB-001467</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An IV infusion of placebo</description>
    <arm_group_label>0.2 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>0.4 mg/kg ARB-001467 or Placebo</arm_group_label>
    <arm_group_label>ARB-001467 or Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documented chronic HBV infection for ≥12 months prior to Screening Visit.

          -  Quantitative HBsAg ≥1000 IU/mL at the Screening Visit.

          -  Subjects currently receiving entecavir and/or tenofovir for ≥12 months and HBV DNA
             undetectable.

        Key Exclusion Criteria:

          -  Known co-infection with HIV, hepatitis C virus, and hepatitis D virus.

          -  Receiving or planning to receive systemic immunosuppressive medications during the
             study or ≤2 months prior to the first dose of study treatment.

          -  Receiving or planning to receive interferon during the study or ≤12 months prior to
             the first dose of study treatment.

          -  Significant immunosuppression from, but not limited to immunodeficiency conditions
             such as common variable hypogammaglobulinemia.

          -  Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months
             prior to the Screening Visit.

          -  Any known pre-existing medical or psychiatric condition that could interfere with the
             subject's ability to provide informed consent or participate in study conduct, or that
             may confound study findings.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Mendez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Arbutus Biopharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monash Health, Gastroenterology and Hepatology</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred, Gastroenterology and Hepatology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

